Cryofocus Medtech (Shanghai) Co., Ltd. (HKG:6922)
Hong Kong · Delayed Price · Currency is HKD 2.665
-0.110 (-3.96%)
Sep 11, 2026, 11:39 AM HKT
HKG:6922 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 84.84 | 95.27 | 53.53 | 40.95 | 27.15 | 22.43 | |
Revenue Growth | -0.38% | 77.97% | 30.72% | 50.83% | 21.06% | 147.69% |
Cost of Revenue | 27.32 | 31.28 | 15.12 | 9.9 | 7.79 | 6.88 |
Gross Profit | 57.52 | 63.98 | 38.41 | 31.05 | 19.36 | 15.55 |
Selling, General & Admin | 64.16 | 76.98 | 95.28 | 74.7 | 88.33 | 55.56 |
Research & Development | 27.74 | 30.44 | 73.46 | 76.13 | 59.93 | 38.85 |
Operating Expenses | 91.9 | 107.41 | 168.74 | 150.82 | 148.26 | 94.41 |
Operating Income | -34.38 | -43.43 | -130.33 | -119.77 | -128.9 | -78.87 |
Interest Expense | -1.71 | -1.95 | -1.09 | -0.65 | -0.59 | -0.38 |
Interest & Investment Income | 0.01 | 0.09 | 0.23 | 1.22 | 1.19 | 2.98 |
Currency Exchange Gain (Loss) | - | - | 1.16 | 1.7 | 2.62 | - |
Other Non Operating Income (Expenses) | 2.66 | 0.84 | 18.89 | 11.75 | 7.36 | 0.74 |
EBT Excluding Unusual Items | -33.42 | -44.46 | -111.14 | -105.75 | -118.32 | -75.52 |
Other Unusual Items | - | - | - | - | - | -50.97 |
Pretax Income | -33.42 | -44.46 | -111.14 | -105.75 | -118.32 | -126.5 |
Income Tax Expense | 0.72 | - | 0.13 | - | - | - |
Earnings From Continuing Operations | -34.14 | -44.46 | -111.28 | -105.75 | -118.32 | -126.5 |
Minority Interest in Earnings | 4.71 | 6.29 | 6.91 | 8.26 | 6.09 | 24.62 |
Net Income | -29.43 | -38.17 | -104.37 | -97.49 | -112.22 | -101.87 |
Net Income to Common | -29.43 | -38.17 | -104.37 | -97.49 | -112.22 | -101.87 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 241 | 239 | 239 | 239 | 228 | 228 |
Shares Outstanding (Diluted) | 241 | 239 | 239 | 239 | 228 | 228 |
Shares Change | 0.98% | - | - | 4.86% | 0.01% | - |
EPS (Basic) | -0.12 | -0.16 | -0.44 | -0.41 | -0.49 | -0.45 |
EPS (Diluted) | -0.12 | -0.16 | -0.44 | -0.41 | -0.49 | -0.45 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | - | -6.59 | -84.79 | -111 | -103.95 | -74.93 |
Free Cash Flow Per Share | - | -0.03 | -0.35 | -0.46 | -0.46 | -0.33 |
Gross Margin | 67.80% | 67.16% | 71.75% | 75.83% | 71.32% | 69.32% |
Operating Margin | -40.52% | -45.59% | -243.46% | -292.48% | -474.77% | -351.68% |
Profit Margin | -34.69% | -40.06% | -194.96% | -238.06% | -413.36% | -454.26% |
Free Cash Flow Margin | - | -6.92% | -158.39% | -271.05% | -382.87% | -334.11% |
EBITDA | -28.29 | -37.38 | -124.06 | -114.35 | -124.34 | -76.14 |
EBITDA Margin | -33.34% | -39.24% | -231.76% | -279.25% | - | - |
D&A For EBITDA | 6.1 | 6.05 | 6.26 | 5.42 | 4.55 | 2.73 |
EBIT | -34.38 | -43.43 | -130.33 | -119.77 | -128.9 | -78.87 |
EBIT Margin | -40.52% | -45.59% | -243.46% | -292.48% | - | - |